← Leaderboards
Jonathan Li
Brigham And Women'S Hospital
$17,759,976
Attributed
$20,334,514
Total exposure
19
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,177,841 · 20
By mechanism
R01$11,922,907 · 4
P01$9,856,951 · 7
R21$1,996,803 · 4
P30$1,651,744 · 2
R56$896,825 · 1
K08$682,200 · 1
Top collaborators
- Ya-Chi Ho4 shared
- Athe M. Tsibris4 shared
- Amy K Barczak3 shared
- Mark J Siedner3 shared
- Jose Ramon Castillo-Mancilla2 shared
- Suzanne Mccluskey2 shared
- Michael Scott Seaman2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Daniel R Kuritzkes$313,891,104
- Linos Vandekerckhove$2,930,865
- Francisco J. Quintana$15,804,456
- Jeffrey Andrew Sparks$7,186,255
- Abraam M. Yakoub$5,179,295
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralAntiretroviral TherapyParticipantResearch PersonnelSamplingCohortDesignAftercareDisease RemissionCellsHiv InfectionsIntegration SitePersonsProgramsPharmaceutical PreparationsViral ReboundClinical TrialsCharacteristicsProvirusesInterruptionInsightViremiaTherapeutic InterventionVirus
Grant awards (53)
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,700,985
P01 · FY2025 · AI · contact PI
HIV Reservoir Ecology of Viral Remission (PTC)$926,815
R01 · FY2025 · AI · contact PI
Characterization of Persistent COVID-19$845,667
R01 · FY2025 · AI · contact PI
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study)$632,214
R01 · FY2025 · AI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 1$462,117
P01 · FY2025 · AI · contact PI
Clinical Core$352,783
P30 · FY2025 · AI · contact PI
Mentoring the next generation of patient-oriented translational virologists$170,411
K24 · FY2025 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Data Analytics & Modeling Core$153,950
P01 · FY2025 · AI · contact PI
Exploring low-level HIV viremia among individuals on dolutegravir in sub-Saharan Africa (Low-V Africa Study)$129,488
R01 · FY2025 · AI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Admin Core$128,154
P01 · FY2025 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,681,120
P01 · FY2024 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$869,936
R01 · FY2024 · AI · contact PI
Characterization of Persistent COVID-19$846,387
R01 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 1$463,009
P01 · FY2024 · AI · contact PI
Clinical Core$354,004
P30 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Data Analytics & Modeling Core$154,245
P01 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Admin Core$127,219
P01 · FY2024 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$2,543
R01 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,721,792
P01 · FY2023 · AI · contact PI
Characterization of Persistent COVID-19$868,661
R01 · FY2023 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$866,695
R01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 1$464,527
P01 · FY2023 · AI · contact PI
Clinical Core$312,942
P30 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Data Analytics & Modeling Core$163,018
P01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Admin Core$143,040
P01 · FY2023 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$82,431
R01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,739,430
P01 · FY2022 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$866,695
R01 · FY2022 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 1$458,032
P01 · FY2022 · AI · contact PI
Clinical Core$308,845
P30 · FY2022 · AI · contact PI
Autologous HIV antibodies for viral control$222,322
R21 · FY2022 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Admin Core$197,202
P01 · FY2022 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Data Analytics & Modeling Core$99,111
P01 · FY2022 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$873,004
R01 · FY2021 · AI · contact PI
Novel virologic and pharmacologic assays to predict clinical outcomes after first-line ART failure in sub-Saharan Africa$770,671
R01 · FY2021 · AI · contact PI
Clinical Core$323,170
P30 · FY2021 · AI · contact PI
Autologous HIV antibodies for viral control$286,535
R21 · FY2021 · AI · contact PI
HIV Reservoir Ecology of Viral Remission$920,378
R01 · FY2020 · AI · contact PI
Novel virologic and pharmacologic assays to predict clinical outcomes after first-line ART failure in sub-Saharan Africa$768,825
R01 · FY2020 · AI · contact PI
Novel virologic and pharmacologic assays to predict clinical outcomes after first-line ART failure in sub-Saharan Africa$798,732
R01 · FY2019 · AI · contact PI
Novel virologic and pharmacologic assays to predict clinical outcomes after first-line ART failure in sub-Saharan Africa$853,765
R01 · FY2018 · AI · contact PI
Single-Cell Analysis of HIV Latency Reversal$282,225
R21 · FY2017 · AI · contact PI
Impact of ART Adherence on HIV Persistence and Inflammation$245,324
R21 · FY2017 · AI
Viral and Immune Determinants of HIV Rebound$896,825
R56 · FY2016 · AI · contact PI
Single-Cell Analysis of HIV Latency Reversal$238,365
R21 · FY2016 · AI · contact PI
Impact of ART Adherence on HIV Persistence and Inflammation$218,906
R21 · FY2016 · AI
Implications of HIV-1 Minority Variants for Virologic Failure and HIV Reservoirs$136,440
K08 · FY2016 · AI · contact PI
Predictors of HIV Control after Antiretroviral Treatment Interruption$220,032
R21 · FY2015 · AI · contact PI
Implications of HIV-1 Minority Variants for Virologic Failure and HIV Reservoirs$136,440
K08 · FY2015 · AI · contact PI
Predictors of HIV Control after Antiretroviral Treatment Interruption$283,094
R21 · FY2014 · AI · contact PI
Implications of HIV-1 Minority Variants for Virologic Failure and HIV Reservoirs$136,440
K08 · FY2014 · AI · contact PI
Implications of HIV-1 Minority Variants for Virologic Failure and HIV Reservoirs$136,440
K08 · FY2013 · AI · contact PI
Implications of HIV-1 Minority Variants for Virologic Failure and HIV Reservoirs$136,440
K08 · FY2012 · AI · contact PI